TherapeuticsMD (TXMD) Total Current Liabilities (2010 - 2026)

TherapeuticsMD has reported Total Current Liabilities for 17 years, with the latest figure at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 3.59% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 3.59% YoY), and the FY2025 full-year result was $4.8 million, down 7.38% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $4.9 million, up from $4.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $264.8 million in Q1 2022, with the low at $4.7 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $44.3 million across 5 years, with a median of $6.5 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 332.14% — and 2023, when it slumped 92.7%.
• TherapeuticsMD's Total Current Liabilities stood at $46.8 million in 2022, then tumbled by 85.37% to $6.9 million in 2023, then decreased by 24.63% to $5.2 million in 2024, then declined by 7.38% to $4.8 million in 2025, then gained by 2.63% to $4.9 million in 2026.
• The last three Total Current Liabilities figures came in at $4.9 million (Q1 2026), $4.8 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.